| Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
| [0074]
|
| Fas ligand-based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth?
| [0074]
|
| CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
| [0074]
|
| Clinical manufacturing of CAR T cells: foundation of a promising therapy
| [0074]
|
| Transgene reactivation in induced pluripotent stem cell derivatives and reversion to pluripotency of induced pluripotent stem cell-derived mesenchymal stem cells
| [0074]
|
| Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential
| [0074]
|